Publicaciones en colaboración con investigadores/as de Institute Curie (30)

2024

  1. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

    Therapeutic Advances in Medical Oncology, Vol. 16

2022

  1. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

    Journal of the National Cancer Institute, Vol. 114, Núm. 1, pp. 109-122

  2. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

    Communications biology, Vol. 5, Núm. 1, pp. 1061

  3. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

    Journal of Clinical Oncology, Vol. 32

  4. Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))

    European journal of human genetics : EJHG

  5. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

    European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362

2021

  1. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer

    New England Journal of Medicine, Vol. 385, Núm. 25, pp. 2336-2347

  2. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 489-498

  3. Common gene variants within 3′-untranslated regions as modulators of multiple myeloma risk and survival

    International Journal of Cancer, Vol. 148, Núm. 8, pp. 1887-1894

2020

  1. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness

    Cancer Research, Vol. 80, Núm. 3, pp. 624-638

  2. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 26, Núm. 15, pp. 3947-3957

  3. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

    JAMA Oncology, Vol. 6, Núm. 8, pp. 1218-1230

  4. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

    Nature Genetics, Vol. 52, Núm. 1, pp. 56-73

  5. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

    Annals of Oncology, Vol. 31, Núm. 8, pp. 1001-1010

  6. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

    Genetic Epidemiology, Vol. 44, Núm. 5, pp. 442-468

2019

  1. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

    Leukemia and Lymphoma, Vol. 60, Núm. 7, pp. 1803-1811

  2. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

    Nature Communications, Vol. 10, Núm. 1

  3. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

    npj Breast Cancer, Vol. 5, Núm. 1

2018

  1. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A Meta-analysis

    Journal of the National Cancer Institute, Vol. 110, Núm. 6, pp. 560-567

2017

  1. Identification of miRSNPs associated with the risk of multiple myeloma

    International Journal of Cancer, Vol. 140, Núm. 3, pp. 526-534